PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axisResearch in context

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axisResearch in context

Background: Inflammatory mediator prostaglandin E2–prostaglandin E2 receptor EP3 (PTGER3) signaling is critical for tumor-associated angiogenesis, tumor growth, and chemoresistance. However, the mechanism underlying these effects in ovarian cancer is not known. Methods: An association between higher...

Full description

Bibliographic Details
Main Authors: Cristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, Burcu Aslan, Junhua Mai, Guangan He, Lingegowda S. Mangala, Dahai Jiang, Archana S. Nagaraja, Bulent Ozpolat, Arturo Chavez-Reyes, Mauro Ferrari, Rahul Mitra, Zahid H. Siddik, Haifa Shen, Xianbin Yang, Anil K. Sood, Gabriel Lopez-Berestein
Format: Article
Language:English
Published: Elsevier 2019-02-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396418305498

Internet

http://www.sciencedirect.com/science/article/pii/S2352396418305498

Similar Items